GC
GPCR icon

GMT Capital’s Structure Therapeutics GPCR Stock Holding History

GMT Capital’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-81,700
Closed -$3.33M – 57
2023
Q4 		$3.33M Sell
81,700
-31,500
-28% -$1.81M 0.13% 38
2023
Q3 		$5.71M Buy
+113,200
New +$3.65M 0.21% 52

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

GMT Capital's GPCR Position: Q1 2024 in Review

GMT Capital sold out of Structure Therapeutics (GPCR) in Q1 2024, closing a stake of 81,700 shares — an estimated $3.33M sold.

GMT Capital first reported a position in GPCR in Q3 2023 and held it in 2 quarters. The position peaked at $5.71M in Q3 2023. 119 funds tracked by Wall St. Rank hold GPCR as of Q1 2024.

  • GMT Capital reported no remaining Structure Therapeutics position as of Q1 2024 after selling out during the quarter.
  • GMT Capital sold 81,700 Structure Therapeutics shares in Q1 2024, an estimated $3.33M.
  • GMT Capital first reported a position in Structure Therapeutics in Q3 2023 and held it in 2 quarters.
  • GMT Capital's Structure Therapeutics position peaked at $5.71M in Q3 2023.
  • 119 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2024.

Based on GMT Capital's 13F filing for Q1 2024, filed 13 May 2024.